177 related articles for article (PubMed ID: 20558841)
41. Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway.
Lu J; Liu X; Liao YP; Wang X; Ahmed A; Jiang W; Ji Y; Meng H; Nel AE
ACS Nano; 2018 Nov; 12(11):11041-11061. PubMed ID: 30481959
[TBL] [Abstract][Full Text] [Related]
42. Inhibition of indoleamine 2,3-dioxygenase suppresses NK cell activity and accelerates tumor growth.
Kai S; Goto S; Tahara K; Sasaki A; Kawano K; Kitano S
J Exp Ther Oncol; 2003; 3(6):336-45. PubMed ID: 14678522
[TBL] [Abstract][Full Text] [Related]
43. Pharmacological Inhibitors of NAD Biosynthesis as Potential An ticancer Agents.
Lucas S; Soave C; Nabil G; Ahmed ZSO; Chen G; El-Banna HA; Dou QP; Wang J
Recent Pat Anticancer Drug Discov; 2017; 12(3):190-207. PubMed ID: 28637419
[TBL] [Abstract][Full Text] [Related]
44. Inhibition of NAMPT markedly enhances plasma-activated medium-induced cell death in human breast cancer MDA-MB-231 cells.
Nagaya M; Hara H; Kamiya T; Adachi T
Arch Biochem Biophys; 2019 Nov; 676():108155. PubMed ID: 31628926
[TBL] [Abstract][Full Text] [Related]
45. Interleukin-6 and indoleamine-2,3-dioxygenase as potential adjuvant targets for Papillomavirus-related tumors immunotherapy.
Pagni RL; Souza PDC; Pegoraro R; Porchia BFMM; da Silva JR; Aps LRMM; Silva MO; Rodrigues KB; Sales NS; Ferreira LCS; Moreno ACR
Front Immunol; 2022; 13():1005937. PubMed ID: 36405719
[TBL] [Abstract][Full Text] [Related]
46. Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells.
Lob S; Konigsrainer A; Schafer R; Rammensee HG; Opelz G; Terness P
Blood; 2008 Feb; 111(4):2152-4. PubMed ID: 18045970
[TBL] [Abstract][Full Text] [Related]
47. Nicotinamide phosphoribosyltransferase: a potent therapeutic target in non-small cell lung cancer with epidermal growth factor receptor-gene mutation.
Okumura S; Sasaki T; Minami Y; Ohsaki Y
J Thorac Oncol; 2012 Jan; 7(1):49-56. PubMed ID: 22089115
[TBL] [Abstract][Full Text] [Related]
48. Antitumor effect of combined NAMPT and CD73 inhibition in an ovarian cancer model.
Sociali G; Raffaghello L; Magnone M; Zamporlini F; Emionite L; Sturla L; Bianchi G; Vigliarolo T; Nahimana A; Nencioni A; Raffaelli N; Bruzzone S
Oncotarget; 2016 Jan; 7(3):2968-84. PubMed ID: 26658104
[TBL] [Abstract][Full Text] [Related]
49. Indoleamine 2, 3-dioxygenase (IDO) is essential for dendritic cell activation and chemotactic responsiveness to chemokines.
Hwang SL; Chung NP; Chan JK; Lin CL
Cell Res; 2005 Mar; 15(3):167-75. PubMed ID: 15780178
[TBL] [Abstract][Full Text] [Related]
50. Uveal melanoma expression of indoleamine 2,3-deoxygenase: establishment of an immune privileged environment by tryptophan depletion.
Chen PW; Mellon JK; Mayhew E; Wang S; He YG; Hogan N; Niederkorn JY
Exp Eye Res; 2007 Nov; 85(5):617-25. PubMed ID: 17870068
[TBL] [Abstract][Full Text] [Related]
51. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape.
Katz JB; Muller AJ; Prendergast GC
Immunol Rev; 2008 Apr; 222():206-21. PubMed ID: 18364004
[TBL] [Abstract][Full Text] [Related]
52. Suppression of leukocyte infiltration and cartilage degradation by selective inhibition of pre-B cell colony-enhancing factor/visfatin/nicotinamide phosphoribosyltransferase: Apo866-mediated therapy in human fibroblasts and murine collagen-induced arthritis.
Evans L; Williams AS; Hayes AJ; Jones SA; Nowell M
Arthritis Rheum; 2011 Jul; 63(7):1866-77. PubMed ID: 21400478
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of indoleamine 2,3-dioxygenase enhances the T-cell response to influenza virus infection.
Fox JM; Sage LK; Huang L; Barber J; Klonowski KD; Mellor AL; Tompkins SM; Tripp RA
J Gen Virol; 2013 Jul; 94(Pt 7):1451-1461. PubMed ID: 23580425
[TBL] [Abstract][Full Text] [Related]
54. Accelerated rejection of the second transplants of immunogenic tumor in mice under inhibition of indoleamine 2,3-dioxygenase activity by ethyl pyruvate.
Vasilyeva ED; Kaledin V; Nikolin VP; Popova NA; Kirilyuk IA; Grigor'ev IA
Exp Oncol; 2012; 34(1):66-8. PubMed ID: 22453153
[TBL] [Abstract][Full Text] [Related]
55. The enhanced antitumour response of pimozide combined with the IDO inhibitor L‑MT in melanoma.
Jia H; Ren W; Feng Y; Wei T; Guo M; Guo J; Zhao J; Song X; Wang M; Zhao T; Wang H; Feng Z; Tian Z
Int J Oncol; 2018 Sep; 53(3):949-960. PubMed ID: 30015838
[TBL] [Abstract][Full Text] [Related]
56. D-MT prompts the anti-tumor effect of oxaliplatin by inhibiting IDO expression in a mouse model of colon cancer.
Zhang Y; Jia H; Liu Z; Guo J; Li Y; Li R; Zhu G; Li J; Li M; Li X; Wang S; Dang C; Zhao T
Int Immunopharmacol; 2021 Dec; 101(Pt A):108203. PubMed ID: 34649091
[TBL] [Abstract][Full Text] [Related]
57. Tumor immune escape mediated by indoleamine 2,3-dioxygenase.
Zamanakou M; Germenis AE; Karanikas V
Immunol Lett; 2007 Aug; 111(2):69-75. PubMed ID: 17644189
[TBL] [Abstract][Full Text] [Related]
58. Genomic and tumor biological aspects of the anticancer nicotinamide phosphoribosyltransferase inhibitor FK866 in resistant human colorectal cancer cells.
Ogino Y; Sato A; Uchiumi F; Tanuma SI
Genomics; 2019 Dec; 111(6):1889-1895. PubMed ID: 30582964
[TBL] [Abstract][Full Text] [Related]
59. NAD metabolism fuels human and mouse intestinal inflammation.
Gerner RR; Klepsch V; Macheiner S; Arnhard K; Adolph TE; Grander C; Wieser V; Pfister A; Moser P; Hermann-Kleiter N; Baier G; Oberacher H; Tilg H; Moschen AR
Gut; 2018 Oct; 67(10):1813-1823. PubMed ID: 28877980
[TBL] [Abstract][Full Text] [Related]
60. 4-Bromophenylhydrazinyl benzenesulfonylphenylureas as indoleamine 2,3-dioxygenase inhibitors with in vivo target inhibition and anti-tumor efficacy.
Lin SY; Yeh TK; Song JS; Hung MS; Cheng MF; Liao FY; Li AS; Cheng SY; Lin LM; Chiu CH; Wu MH; Lin YJ; Hsiao W; Sun M; Wang YH; Huang CH; Tang YC; Chang HH; Huang ZT; Chao YS; Shih C; Pan SL; Wu SY; Kuo CC; Ueng SH
Bioorg Chem; 2018 Apr; 77():600-607. PubMed ID: 29494816
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
